Suppr超能文献

用天然化合物靶向mTOR激酶:通过增强结合机制实现有效的ATP竞争性抑制

Targeting mTOR Kinase with Natural Compounds: Potent ATP-Competitive Inhibition Through Enhanced Binding Mechanisms.

作者信息

Marafie Sulaiman K, Alshawaf Eman, Al-Mulla Fahd, Abubaker Jehad, Mohammad Anwar

机构信息

Biochemistry and Molecular Biology Department, Dasman Diabetes Institute, Dasman 15462, Kuwait.

Translational Research Department, Dasman Diabetes Institute, Dasman 15462, Kuwait.

出版信息

Pharmaceuticals (Basel). 2024 Dec 12;17(12):1677. doi: 10.3390/ph17121677.

Abstract

: The mammalian target of the rapamycin (mTOR) signaling pathway is a central regulator of cell growth, proliferation, metabolism, and survival. Dysregulation of mTOR signaling contributes to many human diseases, including cancer, diabetes, and obesity. Therefore, inhibitors against mTOR's catalytic kinase domain (KD) have been developed and have shown significant antitumor activities, making it a promising therapeutic target. The ATP-KD interaction is particularly important for mTOR to exert its cellular functions, and such inhibitors have demonstrated efficient attenuation of overall mTOR activity. : In this study, we screened the Traditional Chinese Medicine (TCM) database, which enlists natural products that capture the relationships between drugs targets and diseases. Our aim was to identify potential ATP-competitive agonists that target the mTOR-KD and compete with ATP to bind the mTOR-KD serving as potential potent mTOR inhibitors. : We identified two compounds that demonstrated interatomic interactions similar to those of ATP-mTOR. The conformational stability and dynamic features of the mTOR-KD bound to the selected compounds were tested by subjecting each complex to 200 ns molecular dynamic (MD) simulations and molecular mechanics/generalized Born surface area (MM/GBSA) to extract free binding energies. We show the effectiveness of both compounds in forming stable complexes with the mTOR-KD, which is more effective than the mTOR-KD-ATP complex with more robust binding affinities. : This study implies that both compounds could serve as potential therapeutic inhibitors of mTOR, regulating its function and, therefore, mitigating human disease progression.

摘要

雷帕霉素的哺乳动物靶点(mTOR)信号通路是细胞生长、增殖、代谢和存活的核心调节因子。mTOR信号失调会导致许多人类疾病,包括癌症、糖尿病和肥胖症。因此,针对mTOR催化激酶结构域(KD)的抑制剂已被开发出来,并显示出显著的抗肿瘤活性,使其成为一个有前景的治疗靶点。ATP与KD的相互作用对于mTOR发挥其细胞功能尤为重要,这类抑制剂已证明能有效减弱mTOR的整体活性。

在本研究中,我们筛选了传统中药(TCM)数据库,该数据库收录了能体现药物靶点与疾病之间关系的天然产物。我们的目的是识别潜在的ATP竞争性激动剂,这些激动剂靶向mTOR-KD并与ATP竞争结合mTOR-KD,从而作为潜在的强效mTOR抑制剂。

我们鉴定出两种化合物,它们表现出与ATP-mTOR相似的原子间相互作用。通过对每个复合物进行200纳秒的分子动力学(MD)模拟和分子力学/广义玻恩表面积(MM/GBSA)测试,以提取自由结合能,从而检测与所选化合物结合的mTOR-KD的构象稳定性和动力学特征。我们展示了这两种化合物与mTOR-KD形成稳定复合物的有效性,这比mTOR-KD-ATP复合物更有效,且具有更强的结合亲和力。

这项研究表明,这两种化合物都可以作为mTOR的潜在治疗抑制剂,调节其功能,从而减缓人类疾病的进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ad/11677242/a1bfe89ec348/pharmaceuticals-17-01677-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验